Navigation Links
Boston Scientific Announces Two Directors Leave Board as Burns Named CEO of Xerox and Johnson Confirmed as Under Secretary of Energy
Date:5/27/2009

NATICK, Mass., May 27 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that Ursula Burns and Kristina Johnson have resigned from the Company's Board of Directors after accepting senior appointments in industry and government, respectively.

Ms. Burns has been named Chief Executive Officer of the Xerox Corporation, effective July 1, and Dr. Johnson has been confirmed by the U.S. Senate as Under Secretary in the Department of Energy. Prior to their most recent appointments, Ms. Burns was President of Xerox, and Dr. Johnson was Provost and Senior Vice President for Academic Affairs at The Johns Hopkins University.

"Ursula is strongly qualified to assume the role of CEO at Xerox, and Kristina is also exceptionally qualified for her new position in the critical arena of energy policy," said Pete Nicholas, Chairman of the Board of Boston Scientific. "We are grateful for their service to Boston Scientific and its customers, patients and shareholders, and we wish Ursula and Kristina all the best in their future endeavors."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our leadership and corporate governance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A -- Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:  Paul Donovan
              508-650-8541 (office)
              508-667-5165 (mobile)
              Media Relations

              Larry Neumann
              508-650-8696 (office)
              Investor Relations
              Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Transplant Expo Launches in Boston to Educate About Miracle of Transplantation and Address Organ Donor Shortage
2. ALL: Boston Archdiocese Reportedly on Track for Abortion Referring Venture
3. Fitch Raises Boston Scientifics Rating Outlook to Positive
4. SSI Group to Integrate Boston Software Systems Boston WorkStation Into ClickON PREVENT
5. Childrens Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication
6. Joslin Diabetes Center Names Boston Celtics Star Ray Allen to Board of Trustees
7. Glymetrix of Salem Wins 2009 North of Boston Business Plan Competition
8. Boston Scientific to Participate in Piper Jaffray PCR Post-Op Summit
9. Raytheon Donates $100,000 to Fisher House Boston
10. Boston Scientific Announces Schedule for EuroPCR 2009
11. First Boston Pharma, LLC Acquires NutraMax Products, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 19, 2017 , ... At Creekwood Dental Arts, Drs. ... joint (TMJ) treatment and dental implants in Waco, TX, using the latest ... the T-Scan™ by Tekscan®, they can capture details in the oral cavity for accurate ...
(Date:7/20/2017)... Washington (PRWEB) , ... July 19, 2017 , ... ... 11 “surprising habits” that may sometimes lead to, or worsen, varicose veins in ... Aesthetic Center notes that, while avoiding certain not-so-good practices, like excessive sitting or ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... , What Strategic Decisions Do You Need to Consider?, **An FDAnews Webinar**, ... , 42 CFR Part 11, “Final Rule for Clinical Trials Registration and ...
(Date:7/18/2017)... ... , ... Heritage Woods of Benton, a Gardant affordable assisted living community is ... , The community, which is located at 1305 Bailey Lane in Benton, Illinois, serves ... maintain their independence. , The lunch menu will include Hawaiian chicken, meatballs and coleslaw. ...
(Date:7/17/2017)... ... July 17, 2017 , ... McGraw Family Pledges $3 ... and Train Next Generation of Healthcare Clinicians , NORWALK, Connecticut – July 17, ... its legacy of investing in community health by pledging up to $3 million in ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... 10, 2017  The tenth annual BioPharm America™ ... at the Sheraton Boston Hotel, September 26–27. ... to global decision makers and innovative biotech startup companies. ... leaders during two impactful days. BioPharm America is now ... additional networking opportunities with 4,500+ life science industry influencers ...
(Date:7/5/2017)... , July 5, 2017 Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... it has received approval from the Israel Securities Authority to ... (TASE). Oramed common stock will commence trading on the TASE ... the current market capitalization of the Company, it is expected ...
Breaking Medicine Technology: